Ceremony for the dispatch of the first batch of Furmonertinib took place on 03:58am
At 03:58am, March 8th, Allist held a ceremony celebrating the dispatch of the first batch of Furmonertinib in its factory in Jiangsu. Just five days after Furmonertinib was approved for marketing in China, Allist finished the production of the first batch of the new drug that was to be delivered to hospitals and pharmacies for sales across the country through the channels of its strategic partners including Shanghai Pharmaceutical Co., Ltd and Shanghai Pharmaceutical Logistics Center Co., Ltd, at a stunning speed.
Furmonertinib is the third generation of epidermal
growth factor receptor - tyrosine kinase inhibitor (EGFR-TKI). It targets adult
patients who have progressed during or after treatment with EGFR-TKI and
diagnosed with EGFR T790M mutation-positive, locally advanced or metastatic
non-small cell lung cancer (NSCLC). Available study results show that
Furmonertinib will become a strong competitor in the market of third-generation
EGFR-TKIs as it has a significant efficacy and favorable safety. This self-developed
innovative, effective drug originated in China will bring relief to more
patients in need.